Cargando…
Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
Despite the rapid development of CRISPR/Cas9-mediated gene editing technology, the gene editing potential of CRISPR/Cas9 is hampered by low efficiency, especially for clinical applications. One of the major challenges is that chromatin compaction inevitably limits the Cas9 protein access to the targ...
Autores principales: | Liu, Bin, Chen, Siwei, Rose, Anouk La, Chen, Deng, Cao, Fangyuan, Zwinderman, Martijn, Kiemel, Dominik, Aïssi, Manon, Dekker, Frank J, Haisma, Hidde J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954403/ https://www.ncbi.nlm.nih.gov/pubmed/31799598 http://dx.doi.org/10.1093/nar/gkz1136 |
Ejemplares similares
-
Improved genome editing by an engineered CRISPR-Cas12a
por: Ma, Enbo, et al.
Publicado: (2022) -
Bi-PE: bi-directional priming improves CRISPR/Cas9 prime editing in mammalian cells
por: Tao, Rui, et al.
Publicado: (2022) -
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014) -
Targeting HDAC Complexes in Asthma and COPD
por: Zwinderman, Martijn R. H., et al.
Publicado: (2019) -
Discovery of potent and versatile CRISPR–Cas9 inhibitors engineered for chemically controllable genome editing
por: Song, Guoxu, et al.
Publicado: (2022)